Percutaneous “edge-to-edge” leaflet repair in patient with primary mitral valve regurgitation

Abstract

Mitral regurgitation (MR) is the most common left-sided heart valve disease in developed countries with a constantly rising number of patients requiring hospitalization or intervention. Organic MR is defined as a primary structural abnormality of the mitral valve (MV) apparatus which may be caused by a broad set of pathological processes, among which myxomatous degeneration of the leaflets causing MV prolapse is the most common. If left untreated, chronic severe MR leads to serious adverse outcomes, from heart failure to death, but medical therapy is unable to change the natural history of the disease. Surgical correction, by means of valve repair or replacement, is the gold standard for the treatment of symptomatic patients with severe primary MR. However, surgery is not feasible for a large percentage of patients because of old age, reduced left ventricular ejection fraction and the presence of severe comorbidities. Therefore, in recent years, several percutaneous therapeutic alternatives suitable for high or prohibitive surgical risk patients were developed. In this review we discuss the transcatheter treatment of primary MR, from available evidence to technical practice, with a focus on the percutaneous “edge-to-edge” leaflet repair performed with the MitraClip System and the PASCAL Repair System.

Keywords

Degenerative mitral valve disease / mitral regurgitation / mitral insufficiency / MitraClip / PASCAL

References

[1] Nkomo VT,Skelton TN,Scott CG.Burden of valvular heart diseases: a population-based study..Lancet2006;368:1005-11

[2] Baumgartner H,Bax JJ,Hamm C.2017 ESC/EACTS Guidelines for the management of valvular heart disease..Eur Heart J2017;38:2739-91

[3] Iung B.A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease..Eur Heart J2003;24:1231-43

[4] Antoine C,Benfari G,Maalouf JF.Pathophysiology of degenerative mitral regurgitation: new 3-Dimensional imaging insights..Circ Cardiovasc Imaging2018;11:e005971

[5] Adams DH,Falk V.Degenerative mitral valve regurgitation: best practice revolution..Eur Heart J2010;31:1958-66 PMCID:PMC2921508

[6] Freed LA,Levine RA,Evans JC.Prevalence and clinical outcome of mitral-valve prolapse..N Engl J Med1999;341:1-7

[7] Freed LA,Levy D,Evans JC.Mitral valve prolapse in the general population..J Am Coll Cardiol2002;40:1298-304

[8] Kolibash AJ.Progression of mitral regurgitation in patients with mitral valve prolapse..Herz1988;13:309-17

[9] Ma JI,Strachan M,Wong DJ.Predictive factors for progression of mitral regurgitation in asymptomatic patients with mitral valve prolapse..Am J Cardiol2019;123:1309-13

[10] Mirabel M,Baron G,Détaint D.What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?.Eur Heart J2007;28:1358-65

[11] De Bonis M,Alfieri O.Edge-to-edge Alfieri technique for mitral valve repair: which indications?.Curr Opin Cardiol2013;28:152-7

[12] O’Gara P,Lang R,Hung J.The role of imaging in chronic degenerative mitral regurgitation..JACC Cardiovasc Imaging2008;1:221-37

[13] Feldman T,Rinaldi M,Hermiller J.Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort..J Am Coll Cardiol2009;54:686-94

[14] Li CH,Carreras F.Role of imaging techniques in percutaneous treatment of mitral regurgitation..Rev Esp Cardiol (Engl Ed)2016;69:421-36

[15] Eggebrecht H,Puls M,von Bardeleben RS.Risk and outcomes of complications during and after MitraClip implantation: Experience in 828 patients from the German TRAnscatheter mitral valve interventions (TRAMI) registry..Catheter Cardiovasc Interv2015;86:728-35

[16] Praz F,Chrissoheris M,Nickenig G.Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study..Lancet2017;390:773-80

[17] Feldman T,Glower DD,Rinaldi MJ.Percutaneous repair or surgery for mitral regurgitation..N Engl J Med2011;364:1395-406

[18] Feldman T,Elmariah S,Trento A.Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II..J Am Coll Cardiol2015;66:2844-54

[19] Buzzatti N,Denti P,Schiavi D.Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: a propensity-weighted analysis..J Thorac Cardiovasc Surg2019;158:86-94.e1

[20] Lim DS,Feldman T,Herrmann HC.Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair..J Am Coll Cardiol2014;64:182-92

[21] Jorbenadze R,Barthel C,Schlensak C.Percutaneous edge-to-edge mitral valve repair using the new MitraClip XTR System..JACC Cardiovasc Interv2018;11:e93-5

[22] Weinmann K,Rottbauer W.First experience with the MitraClip XTR device for extensive mitral valve prolapse (Barlow’s disease)..EuroIntervention2018;14:e1276-7

[23] Lim DS,Spargias K,O’Neill WW.Transcatheter valve repair for patients with mitral regurgitation: 30-day results of the CLASP study..JACC Cardiovasc Interv2019;12:1369-78

[24] Mazimba S,Kipperman R,Kar S.Six-month outcomes from the multicenter, prospective study with the novel PASCAL transcatheter valve repair system for patients with mitral regurgitation in the CLASP study..J Card Fail2019;25:S6

[25] Kar S,Lim S,Webb J.TCT-91 1-year outcomes from the multicenter, prospective study with the novel PASCAL transcatheter valve repair system for patients with mitral regurgitation in the CLASP study..J Am Coll Cardiol2019;74:B91

[26] Glower DD,Trento A,Bajwa T.Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study..J Am Coll Cardiol2014;64:172-81

[27] Maisano F,Baldus S,Hausleiter J.Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe..J Am Coll Cardiol2013;62:1052-61

[28] Nickenig G,Franzen O,Vanderheyden M.Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry..J Am Coll Cardiol2014;64:875-84

[29] Puls M,Boekstegers P,Ouarrak T.One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry..Eur Heart J2016;37:703-12 PMCID:PMC4761401

[30] Capodanno D,Barbanti M,Laudisa ML.Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair..Am Heart J2015;170:187-95

[31] Sorajja P,Feldman T,Holmes DR Jr.Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report..J Am Coll Cardiol2017;70:2315-27

[32] Sürder D,Gaemperli O,Felix C.Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: the results of the MitraSwiss registry..Heart2013;99:1034-40